(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
04 November 2021 (04.11.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/222479 A1

(51) International Patent Classification:
C12N 5/0783 (2010.01)

(21) International Application Number:
PCT/US2021/029762

(22) International Filing Date:
28 April 2021 (28.04.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/016,907 28 April 2020 (28.04.2020) US

(71) Applicant: **LYELL IMMUNOPHARMA, INC.** [US/US]; 201 Haskins Way, South San Francisco, CA 94080 (US).

(72) Inventors: **VODNALA, Suman Kumar**; 201 Haskins Way, South San Francisco, CA 94080 (US). **EIL, Robert Langland**; 201 Haskins Way, South San Francisco, CA 94080 (US). **RESTIFO, Nicholas P.**; 201 Haskins Way, South San Francisco, CA 94080 (US).

(74) Agent: **KIM, Ji Eun** et al.; STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C, 1100 New York Avenue, NW, Washington, District of Columbia 20005 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

WO 2021/222479 A1

(54) Title: METHODS FOR CULTURING CELLS

(57) Abstract: The preset disclosure provides methods of culturing cells, e.g., pluripotent cells, multipotent cells, and/or immune cells (e.g., T cells, NK cells, and/or TILs) in a medium comprising at least about 5 mM potassium ion, wherein the medium is not hypertonic. In some aspects, the medium is hypotonic. In some aspects, the methods disclosed herein increases the number of less-differentiated cells in the population of cells. In some aspects, the cultured cells are engineered, e.g., to comprise a chimeric antigen receptor or an engineered T cell receptor. In some aspects, the cells are administered to a subject in need thereof.